查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1790252

美國抗生素市場規模、佔有率及趨勢分析報告：按作用機制、類型、藥物類別和細分市場進行預測，2025-2030 年

U.S. Antibiotics Market Size, Share & Trends Analysis Report By Action Mechanism, By Type, By Drug Class, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

美國抗生素市場概況

美國抗生素市場規模預計在 2024 年達到 137.7 億美元，預計在 2025 年至 2030 年期間的複合年成長率為 3.0%，到 2030 年將達到 164.6 億美元。感染疾病的日益普及是市場成長的主要動力。

老年人和慢性疾病患者中感染疾病的普遍性是美國抗生素市場的主要驅動力。到2024年，超過6,000萬美國將年滿65歲或以上，這使得他們更容易感染肺炎、尿道結石和敗血症等感染疾病。此外，糖尿病、癌症和慢性阻塞性肺病（COPD）等慢性疾病的盛行率不斷上升，削弱了免疫系統，增加了對抗生素的需求。根據美國疾病管制與預防中心（CDC）的數據，近60%的美國成年人至少患有一種慢性疾病，這進一步擴大了需要抗生素治療的患者群體。

外科手術和先進醫療干預措施的興起是美國市場抗生素需求成長的主要原因。器官移植、癌症治療和整形外科手術等手術通常具有較高的術後感染疾病風險，因此預防性和治療性抗生素至關重要。醫院和門診機構依靠有效的抗生素方案來減少併發症並改善患者康復。隨著這些手術的可及性不斷擴大，抗生素在確保患者獲得良好治療結果方面發揮更重要的作用，鞏固了其作為現代醫學重要組成部分的地位。

美國抗生素市場蓬勃發展，得益於尖端研發、巨額醫療支出以及對創新的高度重視。美國在開發用於對抗抗藥性的下一代抗生素方面處於全球領先地位，並得到了2012年《立即產生抗生素激勵法案》（GAIN）等計劃的支持。一個顯著的例子是默克與美國國家過敏和感染疾病研究所（NIAID）於2023年達成的合作，旨在開發針對多重抗藥性細菌的新型抗生素。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章美國抗生素市場變數、趨勢與範圍

  • 市場介紹/電網展望
  • 市場規模和成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 美國抗生素市場分析工具
    • 波特分析
    • PESTEL分析

第4章美國抗生素市場：按作用機制的估計與趨勢分析

  • 細分儀表板
  • 美國抗生素市場：作用機制分析（2023 年和 2030 年）
  • 細胞壁合成抑制劑
    • 2018-2030年收益估算與預測
  • 蛋白質合成抑制劑
    • 2018-2030年收益估算與預測
  • DNA合成抑制劑
    • 2018-2030年收益估算與預測
  • RNA合成抑制劑
    • 2018-2030年收益估算與預測
  • 肌酸抑制劑
    • 2018-2030年收益估算與預測
  • 其他
    • 2018-2030年收益估算與預測

第5章：美國抗生素市場類型、估價與趨勢分析

  • 細分儀表板
  • 美國抗生素市場：2023 年和 2030 年類型分析
  • 品牌抗生素
    • 2018-2030年收益估算與預測
  • 非專利藥
    • 2018-2030年收益估算與預測

第6章：美國抗生素市場（依藥物類別分類）、估價與趨勢分析

  • 細分儀表板
  • 美國抗生素市場：2023 年和 2030 年藥物類別分析
  • 頭孢菌素類
    • 2018-2030年收益估算與預測
  • 青黴素
    • 2018-2030年收益估算與預測
  • Fluoroquinolones
    • 2018-2030年收益估算與預測
  • 大環內酯類
    • 2018-2030年收益估算與預測
  • 卡巴培南類
    • 2018-2030年收益估算與預測
  • Aminoglycosides
    • 2018-2030年收益估算與預測
  • 磺胺類藥物
    • 2018-2030年收益估算與預測
  • 7-ACA
    • 2018-2030年收益估算與預測
  • 其他
    • 2018-2030年收益估算與預測

第7章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 公司熱圖分析
  • 公司簡介
    • AbbeVie, Inc.
    • Pfizer Inc.
    • Novartis AG
    • Merck & Co., Inc.
    • Teva Pharmaceutical Industries Ltd.
Product Code: GVR-4-68040-683-7

U.S. Antibiotics Market Summary

The U.S. antibiotics market size was estimated at USD 13.77 billion in 2024 and is projected to reach USD 16.46 billion by 2030, growing at a CAGR of 3.0% from 2025 to 2030. The growing prevalence of infectious diseases is a major factor contributing to market growth.

The increasing prevalence of infections in the elderly and chronically ill significantly drives the U.S. antibiotics market. In 2024, over 60 million Americans were aged 65 or older, a demographic highly susceptible to infections like pneumonia, UTIs, and sepsis. In addition to that, the rising incidence of chronic conditions such as diabetes, cancer, and COPD compromises immune systems, leading to a greater need for antibiotics. According to CDC, nearly 60% of U.S. adults have at least one chronic disease, further expanding the patient base requiring antibiotic treatment.

The increasing number of surgical procedures and advanced medical interventions significantly contribute to the demand for antibiotics in the U.S. market. Procedures such as organ transplants, cancer treatments, and orthopedic surgeries often carry a high risk of post-operative infections, making preventive and therapeutic antibiotics essential. Hospitals and outpatient facilities depend on effective antibiotic regimens to reduce complications and improve patient recovery. As access to these procedures expands, antibiotics play an even more critical role in ensuring positive patient outcomes, solidifying their position as a vital part of modern medical care.

The U.S. antibiotics market is growing due to cutting-edge R&D, substantial healthcare spending, and a strong emphasis on innovation. The country leads globally in developing next-generation antibiotics to counter AMR, supported by policies such as the Generating Antibiotic Incentives Now (GAIN) Act of 2012, which provides incentives such as extended exclusivity periods. A notable instance is the collaboration between Merck and the National Institute of Allergy and Infectious Diseases (NIAID) in 2023 to develop novel antibiotics targeting multidrug-resistant bacteria.

U.S. Antibiotics Market Report Segmentation

This report forecasts revenue growth at country level as well as provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. antibiotics market report on the basis of action mechanism, type, and drug class:

  • Action Mechanism Outlook (Revenue, USD Million, 2018 - 2030)
  • Cell Wall Synthesis Inhibitors
  • Protein Synthesis Inhibitors
  • DNA Synthesis Inhibitors
  • RNA Synthesis Inhibitors
  • Mycolic Acid Inhibitors
  • Others
  • Type Outlook (Revenue, USD Million, 2018 - 2030)
  • Branded Antibiotics
  • Generic Anitbiotics
  • Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
  • Cephalosporins
  • Penicillins
  • Fluoroquinolones
  • Macrolides
  • Carbapenems
  • Aminoglycosides
  • Sulfonamides
  • 7-ACA
  • Other

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
  • 1.4. Information Procurement
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Antibiotics Market Variables, Trends & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. U.S. Antibiotics Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Political landscape
      • 3.4.1.2. Economic and Social landscape
      • 3.4.1.3. Technological landscape
      • 3.4.1.4. Environmental landscape
      • 3.4.1.5. Legal landscape
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Bargaining power of the suppliers
      • 3.4.2.2. Bargaining power of the buyers
      • 3.4.2.3. Threats of substitution
      • 3.4.2.4. Threats from new entrants
      • 3.4.2.5. Competitive rivalry

Chapter 4. U.S. Antibiotics Market: Action Mechanism Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Antibiotics Market: Action Mechanism Analysis, 2023 & 2030 (USD Million)
  • 4.3. Cell Wall Synthesis Inhibitors
    • 4.3.1. Cell Wall Synthesis Inhibitors Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Protein Synthesis Inhibitors
    • 4.4.1. Protein Synthesis Inhibitors Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. DNA Synthesis Inhibitors
    • 4.5.1. DNA Synthesis Inhibitors Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. RNA Synthesis Inhibitors
    • 4.6.1. RNA Synthesis Inhibitors Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Mycolic Acid Inhibitors
    • 4.7.1. Mycolic Acid Inhibitors Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Antibiotics Market: Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Antibiotics Market: Type Analysis, 2023 & 2030 (USD Million)
  • 5.3. Branded Antibiotics
    • 5.3.1. Branded Antibiotics Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Generic Antibiotics
    • 5.4.1. Generic Antibiotics Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. Antibiotics Market: Drug Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Antibiotics Market: Drug Analysis, 2023 & 2030 (USD Million)
  • 6.3. Cephalosporins
    • 6.3.1. Cephalosporins Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Penicillin
    • 6.4.1. Penicillin Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Fluoroquinolones
    • 6.5.1. Fluoroquinolones Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Macrolides
    • 6.6.1. Macrolides Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Carbapenems
    • 6.7.1. Carbapenems Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Aminoglycosides
    • 6.8.1. Aminoglycosides Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.9. Sulfonamides
    • 6.9.1. Sulfonamides Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.10. 7-ACA
    • 6.10.1. 7-ACA Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.11. Others
    • 6.11.1. Mycolic Acid Inhibitors Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Company Heat Map Analysis
  • 7.4. Company Profiles
    • 7.4.1. AbbeVie, Inc.
      • 7.4.1.1. Company Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. Pfizer Inc.
      • 7.4.2.1. Company Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. Novartis AG
      • 7.4.3.1. Company Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. Merck & Co., Inc.
      • 7.4.4.1. Company Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. Teva Pharmaceutical Industries Ltd.
      • 7.4.5.1. Company Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Strategic Initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Antibiotics market 2018 - 2030 (USD Million)
  • Table 3 U.S. antibiotics market: key market driver analysis
  • Table 4 U.S. antibiotics market: key market restraint analysis
  • Table 5 U.S. antibiotics market estimates and forecast, by action mechanism (USD Million)
  • Table 6 U.S. antibiotics market estimates and forecast, by type (USD Million)
  • Table 7 U.S. antibiotics market estimates and forecast, by drug class (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. antibiotics products: market outlook
  • Fig. 10 Diabetic retinopathy competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 U.S. antibiotics driver impact
  • Fig. 16 U.S. antibiotics restraint impact
  • Fig. 17 U.S. antibiotics strategic initiatives analysis
  • Fig. 18 U.S. antibiotics products: Action Mechanism movement analysis
  • Fig. 19 U.S. antibiotics products: Action Mechanism outlook and key takeaways
  • Fig. 20 Cell Wall Synthesis Inhibitors estimates and forecast, 2018 - 2030
  • Fig. 21 Protein Synthesis Inhibitors estimates and forecast, 2018 - 2030
  • Fig. 22 DNA Synthesis Inhibitors estimates and forecast, 2018 - 2030
  • Fig. 23 RNA Synthesis Inhibitors estimate and forecast, 2018 - 2030
  • Fig. 24 Mycolic Acid Inhibitors estimates and forecast, 2018 - 2030
  • Fig. 25 Others estimates and forecast, 2018 - 2030
  • Fig. 26 U.S. antibiotics products: Type movement analysis
  • Fig. 27 U.S. antibiotics products: Type outlook and key takeaways
  • Fig. 28 Branded Antibiotics market estimates and forecasts, 2018 - 2030
  • Fig. 29 General Antibiotics market estimates and forecasts,2018 - 2030
  • Fig. 30 U.S. antibiotics products: Drug class movement analysis
  • Fig. 31 U.S. antibiotics products: Drug class outlook and key takeaways
  • Fig. 32 Cephalosporins market estimates and forecasts, 2018 - 2030
  • Fig. 33 Penicillins market estimates and forecasts,2018 - 2030
  • Fig. 34 Flaoroquinolones market estimates and forecasts,2018 - 2030
  • Fig. 35 Macrolides market estimates and forecasts,2018 - 2030
  • Fig. 36 Carbopenems market estimates and forecasts,2018 - 2030
  • Fig. 37 Aminoglycosides market estimates and forecasts,2018 - 2030
  • Fig. 38 Sulfonamides market estimates and forecasts,2018 - 2030
  • Fig. 39 7-ACA market estimates and forecasts,2018 - 2030
  • Fig. 40 Other market estimates and forecasts,2018 - 2030